Education
About Us
Working with TipRanks
Follow Us
UCB SA (DE:UNC)
:UNC
UNC Stock Chart & Stats
Day’s Range― - ―
52-Week Range€113.75 - €198.15
Previous CloseN/A
Volume50.00
Average Volume (3M)80.00
Market Cap
€30.43B
Enterprise Value€29.66B
Total Cash (Recent Filing)€861.00M
Total Debt (Recent Filing)€3.04B
Price to Earnings (P/E)28.4
Beta0.40
Next Earnings
Jul 24, 2025EPS Estimate
3.75Next Dividend Ex-Date
Apr 25, 2025Dividend Yield0.57%
Share Statistics
EPS (TTM)5.61
Shares Outstanding194,505,660
10 Day Avg. Volume25
30 Day Avg. Volume80
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)N/A
Price to Sales (P/S)3.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€208.38Price Target Upside30.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Earnings PotentialThere is scarcity value for UCB, given very few companies with clear visibility into the value drivers for the next few years, with accelerating and durable earnings potential.
Product LaunchThe Bimzelx launch continues to outperform, driven by strong patient adoption in multiple conditions and improved formulary positioning.
Sales PerformanceBimzelx H2 sales reached €393MM, with US contribution significantly above consensus, indicating strong market performance.
Bears Say
Market CompetitionBimzelx is expected to have meaningful adoption due to its differentiation from Cosentyx.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
15.81%
Mutual Funds
<0.01% Other Institutional Investors
76.48% Public Companies and
Individual Investors
UNC FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was €113.75 and its highest was €198.15 in the past 12 months.
What is UCB SA’s market cap?
UCB SA’s market cap is €30.43B.
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Jul 24, 2025 which is in 110 days.
How were UCB SA’s earnings last quarter?
UCB SA released its earnings results on Feb 27, 2025. The company reported €2.86 earnings per share for the quarter, beating the consensus estimate of €2.587 by €0.273.
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Undervalued.
Does UCB SA pay dividends?
UCB SA pays a Annually dividend of €0.952 which represents an annual dividend yield of 0.57%. See more information on UCB SA dividends here
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is 3.75.
How many shares outstanding does UCB SA have?
UCB SA has 194,505,660 shares outstanding.
What happened to UCB SA’s price movement after its last earnings report?
UCB SA reported an EPS of €2.86 in its last earnings report, beating expectations of €2.587. Following the earnings report the stock price went down -2.472%.
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in DE:UNC
---
Company Description
UCB SA
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Evenity (osteoporosis), and Nayzilam (cluster seizures).
---
UNC Stock 12 Month Forecast
Average Price Target
€208.38
▲(30.85% Upside)
Technical Analysis
Best Analysts Covering UNC
1 Year
1 Year Success Rate
11/11 ratings generated profit
1 Year Average Return
+34.35%
assigned a buy rating 6 months ago
Copying Peter Verdult's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +34.35% per trade.
---